Aster DM Healthcare has announced the end of Mr. Emmanuel David Gootam's tenure as an Independent Director, effective from the close of business on November 9, 2025. This conclusion marks the end of his first term with the company. The announcement was communicated to the BSE and the National Stock Exchange of India, as required under the Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements. Mr. Gootam will also step down from his roles in various board committees, including his position as Chairperson of the Nomination and Remuneration Committee and membership in the Audit and Medical Excellence Committees.

The company has provided detailed disclosures in compliance with the SEBI Master Circular dated November 11, 2024, which outlines the reasons for Mr. Gootam's departure and confirms that he will cease to be an Independent Director upon the completion of his term. Specifics regarding his appointment and cessation date have been shared, though additional personal details and relationships between directors were noted as not applicable in this context.

Aster DM Healthcare, listed under the scrip code 540975 on BSE and ASTERDM on the NSE, continues to uphold transparency with its stakeholders by adhering to regulatory requirements. The company’s commitment to good governance is evident in its communication regarding board changes, ensuring that all necessary information is disclosed in a timely manner. As Mr. Gootam concludes his term, the healthcare provider will likely look to appoint a new independent director to maintain its governance structure.